natgillin/translations-raw huggingface dataset:
Effect on organic anion transporter 3 (OAT3) substrates There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of A771726, suggesting that A771726 is an inhibitor of OAT3 in vivo.
Učinak na supstrate organskog anionskog transportera 3 (OAT3) Zabilježeno je povećanje prosječne Cmax i AUC (1,43 odnosno 1,54 puta) za cefaklor, nakon ponovljenih doza A771726, što ukazuje na to da je A771726 inhibitor OAT3 in vivo.
Other medicines and Leflunomide ratiopharm
Drugi lijekovi i Leflunomid ratiopharm
Your doctor may perform tests to see if you have tuberculosis.
Vaš liječnik može provesti testove kako bi ustanovio imate li tuberkulozu. - ako morate napraviti određenu krvnu pretragu (utvrđivanje razine kalcija).
The efficacy of leflunomide was demonstrated in one controlled, randomised, double blind study 3L01 in 188 patients with psoriatic arthritis, treated at 20 mg/day.
Djelotvornost leflunomida u liječenju psorijatičnog artritisa pokazala se u jednom kontroliranom, randomiziranom, dvostruko slijepom ispitivanju 3L01 na 188 bolesnika s psorijatičnim artritisom.
Leflunomide ratiopharm contains lactose.
Leflunomid ratiopharm sadrži laktozu.
The most frequently reported adverse effects with leflunomide are: mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness, diarrhoea, nausea, vomiting, oral mucosal disorders (e.g. aphthous stomatitis, mouth ulceration), abdominal pain, increased hair loss, eczema, rash (including maculo-papular rash), pruritus, dry skin, tenosynovitis, CPK increased, anorexia, weight loss (usually insignificant), asthenia, mild allergic reactions and elevation of liver parameters (transaminases (especially ALT), less often gamma-GT, alkaline phosphatise, bilirubin).
Najčešće zabilježene nuspojave tijekom primjene leflunomida su: blagi porast krvnog tlaka, leukopenija, parestezija, glavobolja, omaglica, proljev, mučnina, povraćanje, poremećaji sluznice usne šupljine (npr. aftozni stomatitis, ulceracije u ustima), bol u trbuhu, pojačani gubitak kose, ekcem, osip (uključujući makulopapulozni osip), svrbež, suha koža, tenosinovitis, povećanje CPK, anoreksija, gubitak težine (obično beznačajan), astenija, blage alergijske reakcije i porast jetrenih parametara (transaminaze (osobito ALT), manje često gama-GT, alkalna fosfataza, bilirubin).
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of A771726, suggesting that A771726 is an inhibitor of CYP2C8 in vivo.
Zabilježeno je povećanje prosječne Cmax i AUC (1,7 odnosno 2,4 puta) za repaglinid, nakon ponovljenih doza A771726, što ukazuje na to da je A771726 inhibitor CYP2C8 in vivo.
Leflunomide ratiopharm with food, drink and alcohol
Leflunomid ratiopharm s hranom, pićem i alkoholom Leflunomid ratiopharm se može uzeti s hranom ili bez nje.
Leflunomide ratiopharm contains soya lecithin
Leflunomid ratiopharm sadrži sojin lecitin
A randomised, double-blind, parallel-group non-inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide, 10 mg and 20 mg. From the results it can be concluded that efficacy results of the 20 mg maintenance dose were more favourable, on the other hand, the safety results favoured the 10 mg daily maintenance dose.
Randomiziranom, dvostruko slijepom, neinferiornom studijom paralelnih grupa uspoređivala se relativna djelotvornost dviju različitih dnevnih doza održavanja leflunomida, odnosno 10 i 20 mg.
Lactose monohydrate Low-substituted hydroxypropyl cellulose Tartaric acid
Jezgra tablete laktoza hidrat hidroksipropilceluloza, niskosupstituirana tartaratna kiselina natrijev laurilsulfat magnezijev stearat
All elevations resolved, 2 with continuation of both medicinal products and 3 after discontinuation of leflunomide.
Sve su se povišene vrijednosti smanjile u 2 bolesnika koji su nastavili istodobno uzimati oba lijeka i u 3 bolesnika koji su prekinuli uzimati leflunomid.
EU/1/10/654/003 30 film-coated tablets EU/1/10/654/004 100 film-coated tablets
EU/1/10/654/003 30 filmom obloženih tableta EU/1/10/654/004 100 filmom obloženih tableta
White to almost white, round film-coated tablet with a diameter of 8 mm and a break-mark on one side of the tablet.
Bijela do gotovo bijela, okrugla filmom obložena tableta promjera 8 mm, s razdjelnom crtom na jednoj strani tablete, Tableta se može razdijeliti na jednake polovice.
other medicines for rheumatoid arthritis such as antimalarials (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive medicines (e.g. methotrexate) as these combinations are not advisable, - warfarin and other oral medicines used to thin the blood, as monitoring is necessary to reduce the risk of side effects of this medicine - teriflunomide for multiple sclerosis - repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes - daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer - duloxetine for depression, urinary incontinence or in kidney disease in diabetics - alosetron for the management of severe diarrhoea - theophylline for asthma - tizanidine, a muscle relaxant - oral contraceptives (containing ethinylestradiol and levonorgestrel) - cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections - indomethacin, ketoprofen for pain or inflammation - furosemide for heart disease (diuretic, water pill) - zidovudine for HIV infection
metotreksat) jer se ne savjetuje primjena tih kombinacija. - varfarin i druge oralne lijekove koji se koriste za razrjeđivanje krvi, jer je potrebno praćenje kako bi se smanjio rizik od nuspojava tih lijekova - teriflunomid za liječenje multiple skleroze - repaglinid, pioglitazon, nateglinid ili roziglitazon za liječenje šećerne bolesti - daunorubicin, doksorubicin, paklitaksel ili topotekan za liječenje raka - duloksetin za liječenje depresije, nesposobnosti zadržavanja mokraće ili bolesti bubrega u oboljelih od šećerne bolesti - alosetron za liječenje teškog proljeva - teofilin za liječenje astme - tizanidin, lijek za opuštanje mišića - oralni kontraceptivi (koji sadrže etinilestradiol i levonorgestrel) - cefaklor, benzilpenicilin (penicilin G), ciprofloksacin, za liječenje infekcija - indometacin, ketoprofen za liječenje boli ili upale - furosemid za liječenje bolesti srca (diuretik, tableta za vodu)
EU/1/10/654/001 30 film-coated tablets EU/1/10/654/002 100 film-coated tablets
EU/1/10/654/001 30 filmom obloženih tableta EU/1/10/654/002 100 filmom obloženih tableta
All of these also resolved, 2 with continuation of both medicinal products and 3 after discontinuation of leflunomide.
Sve su se te vrijednosti smanjile u 2 bolesnika koji su nastavili istodobno uzimati oba lijeka i u 3 bolesnika koji su prekinuli uzimati leflunomid.
- diarrhoea, - colitis, - nausea, vomiting, - inflammation of the mouth or mouth ulcers, - abdominal pain, - an increase in some liver test results, - increased hair loss, - eczema, dry skin, rash, itching, - tendonitis (pain caused by inflammation in the membrane surrounding the tendons usually in the feet or hands), - an increase of certain enzymes in the blood (creatine phosphokinase), - problems in the nerves of the arms or legs (peripheral neuropathy).
- abnormalne kožne reakcije kao trnci (parestezije), - blaži porast krvnog tlaka, - proljev, - kolitis, - mučnina, povraćanje, - upala u ustima ili čirevi u ustima, - bol u trbuhu, - porast vrijednosti određenih jetrenih enzima, - pojačan gubitak kose, - ekcem, suha koža, osip, svrbež, - tendinitis (bol uzrokovana upalom membrana koje okružuju tetive obično na stopalima ili rukama), - porast koncentracije određenih enzima u krvi (kreatin fosfokinaze), - problemi sa živcima u rukama ili nogama (periferna neuropatija).
Leflunomide ratiopharm 10 mg film-coated tablets are white to almost white and round with a diameter of about 6 mm.
Kako Leflunomid ratiopharm izgleda i sadržaj pakiranja Leflunomid ratiopharm 10 mg filmom obložene tablete su bijele do gotovo bijele i okrugle, promjera oko 6 mm.
Leflunomide ratiopharm 20 mg film-coated tablets are white to almost white and round with a diameter of about 8 mm and a break-mark on one side of the tablet.
Kako Leflunomid ratiopharm izgleda i sadržaj pakiranja Leflunomid ratiopharm 20 mg filmom obložene tablete su bijele do gotovo bijele i okrugle, promjera 8 mm, s razdjelnom crtom na jednoj strani tablete.
anaemia, mild thrombocytopenia (platelets <100 G/L)
Manje često: anemija, blaga trombocitopenija (trombociti <100 g/l).
Drinking alcohol while taking Leflunomide ratiopharm may increase the chance of liver damage.
Za vrijeme liječenja Leflunomidom ratiopharm ne preporučuje se konzumacija alkohola.Uzimanje alkohola za vrijeme liječenja Leflunomidom ratiopharm može povećati mogućnost oštećenja jetre.
The concentration may be expected to decrease below 0.02 mg/L about 2 years after stopping the treatment with leflunomide.
Smanjenje koncentracije A771726 u plazmi na razinu nižu od 0,02 mg/l očekuje se za oko dvije godine nakon prekida liječenja leflunomidom.
Tel: +39 02 891 798 1
Teva Italia S.r.l. Tel: +39 02 891 798 1
What you need to know before you take Leflunomide ratiopharm Do not take Leflunomide ratiopharm if you have ever had an allergic reaction to leflunomide (especially a serious skin reaction, often accompanied by fever, joint pain, red skin stains, or blisters e.g. Stevens-Johnson syndrome), to peanut or soya or to any of the other ingredients of this medicine (listed in section if you have any liver problems, if you have moderate to severe kidney problems, if you have severely low numbers of proteins in your blood (hypoproteinaemia), if you suffer from any problem which affects your immune system (e.g. AIDS), if you have any problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets, if you are suffering from a serious infection, if you are pregnant, think you may be pregnant, or are breast-feeding.
npr. Steven-Johnsonov sindrom), na kikiriki ili soju ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.), - ako imate probleme s jetrom, - ako imate umjerene do teške probleme s bubrezima, - ako imate izrazito niske vrijednosti proteina u krvi (hipoproteinemija), - ako bolujete od bilo koje bolesti koja utječe na Vaš imunološki sustav (npr. AIDS), - ako imate bilo kakvih problema s koštanom srži ili ako imate smanjen broj crvenih ili bijelih krvnih stanica ili krvnih pločica (trombocita), - ako imate jaku infekciju, - ako ste trudni, mislite da biste mogli biti trudni ili dojite.
Film-coated tablet 30 film-coated tablets 100 film-coated tablets
OBLIK I SADRŽAJ Filmom obložena tableta 30 filmom obloženih tableta 100 filmom obloženih tableta NAČIN I PUT(EVI) PRIMJENE LIJEKA Kroz usta.
Certain vaccinations should not be given while taking Leflunomide ratiopharm, and for a certain amount of time after stopping treatment.
Za vrijeme uzimanja Leflunomida ratiopharm kao i određeno vrijeme nakon prekida liječenja ne smije se provoditi cijepljenje određenim cjepivima.
a decrease in the number of red blood cells (anaemia) and a decrease in the number of blood platelets (thrombocytopenia), - a decrease in the levels of potassium in the blood, - anxiety, - taste disturbances, - urticaria (nettle rash), - tendon rupture, - an increase in the levels of fat in the blood (cholesterol and triglycerides), - a decrease in the levels of phosphate in the blood.
(trombocitopenija), - smanjenje koncentracije kalija u krvi, - tjeskoba, - poremećaji okusa, - koprivnjača (urtikarija), - ruptura tetiva, - povećanje razine masnoća u krvi (kolesterol i trigliceridi), - smanjenje razine fosfata u krvi.
The long half-life of leflunomide should be considered when contemplating administration of a live attenuated vaccine after stopping Leflunomide ratiopharm.
Kad se razmatra primjena živih atenuiranih cjepiva nakon prekida liječenja lijekom Leflunomid ratiopharm, potrebno je uzeti u obzir dugi poluvijek leflunomida.
One film-coated tablet contains 20 mg of leflunomide.
Jedna filmom obložena tableta sadrži 20 mg leflunomida.
Leflunomide ratiopharm is for oral use.
Leflunomid ratiopharm je za peroralnu primjenu.
A randomised study assessed the clinical efficacy response rate in DMARD-naïve patients (n = 121) with early RA, who received either 20 mg or 100 mg of leflunomide in two parallel groups during the initial three day double blind period.
Bolesnici su podijeljeni u dvije paralelne skupine i dobivali su ili 20 mg ili 100 mg leflunomida tijekom prva tri dana dvostruko slijepog ispitivanja.
diarrhoea, nausea, vomiting, oral mucosal disorders (e.g., aphthous stomatitis, mouth ulceration), abdominal pain; colitis including microscopic colitis such as lymphocytic colitis, collagenous colitis
proljev, mučnina, povraćanje, poremećaji sluznice usne šupljine (npr. aftozni stomatitis, ulceracije u ustima), bol u trbuhu; kolitis, uključujući mikroskopski kolitis poput limfocitnog kolitisa, kolagenog kolitisa Manje često: poremećaji okusa
3°years
6.3 Rok valjanosti
(pancytopenia), - severe increase in blood pressure, - inflammation of the lung (interstitial lung disease), - an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice, - severe infections called sepsis which may be fatal, - an increase of certain enzymes in the blood (lactate dehydrogenase).
Rijetke nuspojave (mogu se javiti u do 1 na 1000 ljudi): - povećanje broja krvnih stanica koje se zovu eozinofili (eozinofilija); blago smanjenje broja bijelih krvnih stanica (leukopenija); smanjenje broja svih krvnih stanica (pancitopenija), - izraziti porast krvnog tlaka, - upala pluća (intersticijska plućna bolest), - povećanje rezultata u rezultatima nekih jetrenih testova što se može razviti u ozbiljna stanja poput hepatitisa i žutice, - teške infekcije, uključujući sepsu, koje mogu biti dovesti do smrtnog ishoda, - povećanje enzima laktat dehidrogenaze u krvi.
Tablet 30 tablets 100 tablets
Tableta 30 tableta 100 tableta NAČIN I PUT(EVI) PRIMJENE LIJEKA Kroz usta.
Reproductive system and breast disorders Not known:
Poremećaji reproduktivnog sustava i dojki
- a slight decrease in the number of white blood cells (leucopenia), - mild allergic reactions, - loss of appetite, weight loss (usually insignificant), - tiredness (asthenia), - headache, dizziness, - abnormal skin sensations like tingling (paraesthesia), - mild increase in blood pressure,
Česte nuspojave (mogu se javiti u do 1 na 10 ljudi) - blago smanjeni broj bijelih krvnih stanica (leukopenija), - blaže alergijske reakcije, - gubitak apetita, gubitak težine (obično beznačajan), - umor (astenija), - glavobolja, omaglica,
Pregnancy must be excluded before start of treatment with leflunomide,
Prije liječenja leflunomidom mora se isključiti trudnoća
Alanine aminotransferase (ALT) or serum glutamopyruvate transferase (SGPT) and a complete blood cell count, including a differential white blood cell count and a platelet count, must be checked simultaneously and with the same frequency: before initiation of leflunomide, every two weeks during the first six months of treatment, and every 8 weeks thereafter (see section 4.4).
Alanin aminotransferazu (ALT) ili serumsku glutamopiruvat transferazu (SGPT) i kompletnu krvnu sliku, uključujući diferencijalnu bijelu krvnu sliku i broj trombocita, mora se provjeravati istodobno i u jednakim intervalima:
How to store Leflunomide ratiopharm
Kako čuvati Leflunomid ratiopharm
How to take Leflunomide ratiopharm
Kako uzimati Leflunomid ratiopharm
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg. After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥30% (p=0.02).
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: <20 kg, 20-40 kg i >40 kg.
ratiopharm GmbH
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET ratiopharm GmbH
- a marked decrease of some white blood cells (agranulocytosis), - severe and potentially severe allergic reactions, - inflammation of the small vessels (vasculitis, including cutaneous necrotizing vasculitis), - inflammation of the pancreas (pancreatitis), - severe liver injury such as liver failure or necrosis which may be fatal,
Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 ljudi) - izrazito smanjenje broja pojedinih bijelih krvnih stanica (agranulocitoza), - teške i potencijalno teške alergijske reakcije, - upala malih krvnih žila (vaskulitis, uključujući kožni nekrotizirajući vaskulitis), - upala gušterače (pankreatitis), - teške ozljede jetre kao što su zatajenje jetre ili nekroza koje mogu završiti i smrtnim ishodom, - teške i ponekad po život opasne reakcije (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, multiformni eritem).
Leflunomide ratiopharm 20 mg film-coated tablets Leflunomide
Leflunomid ratiopharm 20 mg filmom obložene tablete leflunomid
Leflunomide ratiopharm 10 mg film-coated tablets Leflunomide
Leflunomid ratiopharm 10 mg filmom obložene tablete leflunomid
The extent of leflunomide absorption is not affected if it is taken with food.
Istodobno uzimanje s hranom ne ometa opseg apsorpcije leflunomida.
Leflunomide ratiopharm 10 mg tablets Leflunomide
NAZIV LIJEKA Leflunomid ratiopharm 10 mg tablete leflunomid NAVOĐENJE DJELATNE/IH
Tablet core
zatajenje bubrega
Leflunomide ratiopharm 20 mg tablets Leflunomide
NAZIV LIJEKA Leflunomid ratiopharm 20 mg tablete leflunomid NAVOĐENJE DJELATNE/IH
Leflunomide ratiopharm 10 mg film-coated tablets
NAZIV LIJEKA Leflunomid ratiopharm 10 mg filmom obložene tablete
- if you are male and wish to father a child. As it can not be excluded that Leflunomide ratiopharm passes into semen, reliable contraception should be used during treatment with Leflunomide ratiopharm.
Budući da se ne može isključiti izlučivanje Leflunomida ratiopharm u spermu, tijekom terapije Leflunomidom ratiopharm treba primjenjivati učinkovitu kontracepciju.
agranulocytosis
Vrlo rijetko: agranulocitoza
Leflunomide ratiopharm 20 mg film-coated tablets
NAZIV LIJEKA Leflunomid ratiopharm 20 mg filmom obložene tablete
- an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells
Manje česte nuspojave (mogu se javiti u do 1 na 100 ljudi) - smanjeni broj crvenih krvnih stanica (anemija) i smanjenje broja krvnih pločica
Fish Oil 0.5ml/Ml
Riblje ulje 0,5ml/Ml
Omega-3-Acid Ethyl Esters 90 With A Specific Composition For Epa And Dha Not Lower Than 85%.
Etil esteri omega-3 kiseline 90 s posebnim sastavom za Epa i Dha koji nije niži od 85 %.
500mg Capsule
500mg kapsula
Fish Oil 1000mg Capsule
Riblje ulje 1000mg kapsula
1000mg Capsule
1000mg kapsula
Esters Of Unsaturated Fatty Acids 500mg Capsule
Esteri nezasićenih masnih kiselina 500mg kapsula
Ratiopharm Gmbh Omega-3 Ratiopharm Omega-3-Acid Ethyl Esters 90 1000mg
Ratiopharm Gmbh Omega-3 Ratiopharm Etil esteri omega-3 kiseline 90 1000mg kapsula
Triglycerides Medium Chain 1qs Capsule, Lecithin Soya 1qs Capsule, Omega-3-Acid Ethyl Esters 90 1000mg Capsule
Srednji lanac triglicerida 1qs kapsula, sojin lecitin 1qs kapsula, etil esteri omega-3 kiseline 90
Omega-3 Fatty Acids 1000mg Capsule
Omega-3 masne kiseline 1000mg kapsula
Oral Emulsion
Oralna emulzija
Esters Of Unsaturated Fatty Acids 1000mg Capsule
Esteri nezasićenih masnih kiselina 1000mg kapsula
Ácidos Omega 3 Aristo Omega-3-Acid Ethyl Esters 1000mg Capsule
Ácidos Omega 3 Aristo Etil esteri omega-3 kiseline 1000mg kapsula
Eicosapentaenoic Acid 791mg/5ml, Vitamin A 100 I.U.G
I.U./G.,eikosapentenoič na kiselina 791mg/5ml, Vitamin A 100 I.U./G.
Docosahexaenoic Acid 265mg/5ml, Eicosapentaenoic Acid 390mg/5ml
Dokosaheksanoična kiselina 265mg/5ml, eikosapentenoična kiselina 390mg/5ml
Docosahexaenoic Acid 115mg Capsule, Vitamin D 1 I.U.G,
Dokosaheksanoična kiselina 115mg kapsula, Vitamin D 1
Eicosapentaenoic Acid 170mg Capsule, Vitamin A 1 I.U.G
I.U./G.,eikosapentenoič na kiselina 170mg kapsula, Vitamin A 1 I.U./G.
Docosahexaenoic Acid 115mg Capsule, Eicosapentanoic Acid/Docosahexaenoic Acid 170mg Capsule
Dokosaheksanoična kiselina 115mg kapsula, eikosapentenoična kiselina/dokosaheksanoi čna kiselina 170mg kapsula
Docosahexaenoic Acid 527mg/5ml, Vitamin D 10 I.U.G,
Dokosaheksanoična kiselina 527mg/5ml, Vitamin D 10
Docosahexaenoic Acid 60mg Capsule, Eicosapentaenoic Acid 90mg Capsule
Dokosaheksanoična kiselina 60mg kapsula, eikosapentenoična kiselina 90mg kapsula
Acidos Omega 3 Stada Omega-3-Acid Ethyl Esters 90 1000mg
Acidos Omega 3 Stada Etil esteri omega-3 kiseline 90 1000mg kapsula
Docosahexaenoic Acid 120mg Capsule, Eicosapentaenoic Acid 180mg Capsule
Dokosaheksanoična kiselina 120mg kapsula, eikosapentenoična kiselina 180mg kapsula
Docosahexaenoic Acid 527mg/5ml, Eicosapentanoic Acid/Docosahexaenoic Acid 791mg/5ml
Dokosaheksanoična kiselina 527mg/5ml, eikosapentenoična kiselina/dokosaheksanoi čna kiselina 791mg/5ml
Docosahexaenoic Acid 527mg/5ml, Eicosapentaenoic Acid 791mg/5ml
Dokosaheksanoična kiselina 527mg/5ml, eikosapentenoična kiselina 791mg/5ml
Docosahexaenoic Acid Ethyl Ester 437mg Capsule
Etil ester eikosapentenoične kiseline 430mg kapsula, etil ester dokosaheksanoične kiseline 437mg kapsula
Docosahexaenoic Acid 115mg Capsule, Eicosapentaenoic Acid 170mg Capsule
Dokosaheksanoična kiselina 115mg kapsula, eikosapentenoična kiselina 170mg kapsula
Docosahexaenoic Acid Ethyl Ester 380mg Capsule
Etil ester eikosapentenoične kiseline 460mg kapsula, etil ester dokosaheksanoične kiseline 380mg kapsula
Ácidos Omega 3 Tarbis Docosahexaenoic Acid 380mg Capsule,
Ácidos Omega 3 Tarbis Dokosaheksanoična kiselina 380mg kapsula, eikosapentenoična kiselina 460mg kapsula, etil esteri omega-3 kiseline 90 1000mg tableta
Eicosapentaenoic Acid 170mg Capsule, Vitamin A 100 I.U.G
Dokosaheksanoična kiselina 115mg kapsula, Vitamin D 10 I.U./G., eikosapentenoična kiselina 170mg kapsula, Vitamin A 100 I.U./G.
Eicosapentaenoic Acid
Oralna otopina
Pharmaceutical Form Route of administration
Farmaceutski oblik
This summary was last updated in 11-2016.
Ovaj sažetak posljednji je put ažuriran u 11.2016.
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Tu će dozu možda trebati povećati nakon jednoga ili dva tjedna do 45 mg jednom dnevno ako je potrebna veća kontrola glukoze u krvi (šećera).
The full EPAR for Pioglitazone Actavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Cjeloviti EPAR za lijek Pioglitazone Actavis nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that Pioglitazone Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
To znači da je Pioglitazone Actavis sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Actos.
As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes.
Posljedica je smanjenje razine glukoze u krvi, što pomaže u kontroli dijabetesa tipa 2.
At subsequent reviews prescribers should confirm that benefits to patients are maintained.
U naknadnim procjenama liječnici koji propisuju terapiju trebali bi potvrditi da i dalje postoje koristi za bolesnike.
The active substance in Pioglitazone Actavis, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Djelatna tvar u lijeku Pioglitazone Actavis, pioglitazon, čini stanice (masti, mišića i jetre) osjetljivijima na inzulin, što znači da tijelo bolje iskorištava inzulin koji proizvodi.
Pioglitazone Actavis is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Lijek Pioglitazone Actavis primjenjuje se za liječenje dijabetesa tipa 2 u odraslih osoba (u dobi od 18 godina ili starijih), osobito u onih prekomjerne tjelesne težine.